The percentages of alterations in these genes among prostate cancer varied from 13-30% for individual genes (CAP2, 19%; CAP1, 13%; CFL1, 30%; CFL2, 21%; DSTN, 19%) (Figure 12A, Table 7); the CFL1 gene was amplified predominantly in the prostate cancer type. This evidence concerns the gene CFL1 and prostate cancer.